Hemenway Trust Co LLC Increases Stock Holdings in Eli Lilly and Company $LLY

Key Points

• Hemenway Trust Co LLC increased its stake in Eli Lilly by 36.0% in Q4, buying an additional 6,370 shares to hold 24,077 shares valued at $25,875,000, making LLY roughly 2.0% of Hemenway's portfolio (its 21st largest holding).
• Eli Lilly posted a blowout Q1—EPS of $8.55 vs. $6.97 consensus and revenue of $19.80 billion (+55.5% YoY)—and raised FY2026 guidance to 35.500–37.000 EPS, driven largely by strong Mounjaro/Zepbound sales and manufacturing investment.
• Institutions own about 82.53% of LLY and analysts rate the stock a consensus "Moderate Buy" with a $1,217.59 target; the company also declared a quarterly dividend of $1.73 ($6.92 annual, ~0.7% yield).

Hemenway Trust Co LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 36.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 24,077 shares of the company's stock after buying an additional 6,370 shares during the quarter. Eli Lilly and Company accounts for approximately 2.0% of Hemenway Trust Co LLC's holdings, making the stock its 21st largest holding. Hemenway Trust Co LLC's holdings in Eli Lilly and Company were worth $25,875,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of LLY. Capital Research Global Investors raised its holdings in shares of Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company's stock valued at $19,141,787,000 after buying an additional 4,332,008 shares during the period. Vanguard Group Inc. raised its holdings in shares of Eli Lilly and Company by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company's stock valued at $88,087,193,000 after buying an additional 1,006,885 shares during the period. Amundi raised its holdings in shares of Eli Lilly and Company by 27.1% during the 3rd quarter. Amundi now owns 4,525,902 shares of the company's stock valued at $3,823,977,000 after buying an additional 964,675 shares during the period. Jennison Associates LLC raised its holdings in shares of Eli Lilly and Company by 22.3% during the 4th quarter. Jennison Associates LLC now owns 5,133,676 shares of the company's stock valued at $5,517,059,000 after buying an additional 937,204 shares during the period. Finally, Victory Capital Management Inc. raised its holdings in shares of Eli Lilly and Company by 47.6% during the 3rd quarter. Victory Capital Management Inc. now owns 2,309,006 shares of the company's stock valued at $1,761,772,000 after buying an additional 744,868 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

LLY stock opened at $974.82 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95. The stock's 50 day moving average is $943.90 and its two-hundred day moving average is $990.90. The company has a market capitalization of $918.03 billion, a PE ratio of 34.63, a P/E/G ratio of 1.08 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same period in the previous year, the business earned $3.34 EPS. Eli Lilly and Company's revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts predict that Eli Lilly and Company will post 35.68 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company's payout ratio is 24.58%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on LLY shares. Scotiabank reiterated an "outperform" rating and set a $1,300.00 target price on shares of Eli Lilly and Company in a report on Thursday, February 5th. Morgan Stanley restated an "overweight" rating and set a $1,344.00 price objective on shares of Eli Lilly and Company in a report on Friday, May 1st. Loop Capital set a $1,200.00 price objective on Eli Lilly and Company in a report on Tuesday, February 10th. UBS Group restated a "buy" rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Finally, Weiss Ratings upgraded Eli Lilly and Company from a "buy (b-)" rating to a "buy (b)" rating in a report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $1,217.59.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q1 beat-and-raise: Lilly reported a blowout Q1 (strong EPS and +56% revenue growth driven by Mounjaro/Zepbound/Foundayo) and raised guidance, a primary driver of recent positive sentiment. LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits?
• Positive Sentiment: Commercial momentum: Mounjaro became the world’s top‑selling drug in Q1 (multi‑billion sales) supporting revenue durability and margin expansion expectations. Eli Lilly Now Has the World's Best-Selling Drug -- But Does That Make the Stock a No-Brainer Buy?
• Positive Sentiment: Manufacturing buildout: Lilly committed another $4.5B to Indiana manufacturing (over $21B since 2020) to secure supply for APIs and genetic medicines — reduces production risk and supports volume growth. Lilly commits additional $4.5 billion across Indiana manufacturing sites
• Positive Sentiment: Clinical progress beyond obesity: New LUCENT-3 data for Omvoh (mirikizumab) showing durable disease clearance in ulcerative colitis supports pipeline diversification and long‑term growth. Eli Lilly Advances As Inflammatory Bowel Disease Drug Reinforces Long-Term Confidence
• Neutral Sentiment: Governance vote: Shareholders upheld the board and current governance structure at the May 4 annual meeting — removes near‑term activist/governance uncertainty. Eli Lilly Shareholders Back Board, Maintain Governance Structure
• Neutral Sentiment: Analyst tone: Several firms reiterated buy/strong‑buy views (Guggenheim; analysts highlight growth profile), which supports the bull case but also reflects already elevated expectations. Guggenheim Reiterates "Buy" Rating for Eli Lilly and Company NYSE: LLY
• Negative Sentiment: Competition and market share risk: Novo Nordisk’s strong pill data and raised guidance highlight intensifying competition (oral GLP‑1s and Wegovy momentum) that could pressure pricing and growth expectations for Lilly. Novo and Lilly gain on signs weight-loss pills could expand the market
• Negative Sentiment: Safety report & market reaction: An adverse event report involving hepatic failure tied to Foundayo prompted investor caution; Wolfe Research says the market reaction may be overdone, but the item still adds short‑term volatility. Wolfe Research Says Market Reaction on Eli Lilly (LLY) Foundayo Report Appears Overdone
• Negative Sentiment: Market chatter on financing: Reports that Lilly might sell bonds (~$8B) to fund deals introduced funding/strategy questions (company provided updates), creating short‑term investor unease. Update: Market Chatter: Eli Lilly Plans to Sell About $8 Billion of Bonds to Fund Acquisitions

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.